2009 – Professor John Hunter publishes a comparison of the human and horse gut. This leads to the identification of low pancreatic enzyme activity and too-rapid digestion as possible explanations for horse digestion problems.​

2010/11 – Prof Hunter and Dr Rosemary Waring identify enzyme rich malt extract as a source of enzymes to compensate for lack of adequate pancreatic enzyme activity in horses.

2012 – Enzyme rich malt extract is tested in horses at a flat racing yard ranked in the top 5 in the UK. The horses show significantly improved condition and run better. Careful stool analysis shows a drop in acetate, which means nutrients are being better absorbed in the gut.

2013 – The trial racing yard puts all his horses on enzyme rich malt extract.

2015 – A pilot study in laminitis helps to identify a potential biomarker for detection of the condition. A different study, managed through a separate company, tests enzyme rich malt extract in humans who have similar problems: the results are positive.

2016 – Tharos Ltd is formed to commercialise enzyme rich malt extract.

2016 to 2018 – EquiNectar® is developed and the scientific programme is consolidated. The clinical and product development programme is optimised to focus on laminitis and wider animal health.

2020 - Commercial sales of EquiNectar® to horseracing yards begins in UK and Ireland.

2021 - Recruitment of National Sales Manager - Tim Jones - to lead the business development in UK horseracing

2022 - Recruitment of senior horseracing vet - Dr Mark Bowen - to our advisory team